and chemotherapy US patent 6,399,063 &mdash Monoclonal antibodies directed to the HER2 receptor US patent 6,387,371 &mdash Monoclonal antibodies directed to the HER2 receptor US patent 6,348,352 ... US patent 6,339,151 &mdash Enzyme catalyzed therapeutic agents US patent 6,333,169 &mdash HER2 extracellular ... &mdash Monoclonal antibodies directed to the HER2 receptor US patent 6,159,706 &mdash Application of enzyme prodrugs as anti infective agents US patent 6,015,567 &mdash HER2 extracellular domain ... antibodies directed to the HER2 receptor US patent 5,720,954 &mdash Monoclonal antibodies directed to the HER2 receptor US patent 5,710,255 &mdash Characterization of a novel anti p110.sup.RB monoclonal antibody US patent 5,677,171 &mdash Monoclonal antibodies directed to the HER2 receptor US patent ... more details
HER2 protein. This type of cancer is known as HER2 positive , HER2 , or HER2 overexpressing . HER2 tumors tend to grow and spread more quickly than tumors that are not HER2 . In 2006, Herceptin was approved for the adjuvant treatment of HER2 breast cancer. ref www.herceptin.com http www.herceptin.com ... more details
PBB geneid 2064 HER2 Human Epidermal Growth Factor Receptor 2 also known as Neu , ErbB 2 , CD340 cluster of differentiation 340 or p185 is a protein that in humans is encoded by the ERBB2 gene . HER2 is a member ... Biomarker medicine biomarker and target of therapy for the disease. Function Gene HER2 is encoded ... . HER2 is named because it has a similar structure to human epidermal growth factor receptor, or HER1 ... found to code for EGFR. Gene cloning showed that HER2, Neu, and ErbB 2 are all encoded by the same ... members, HER2 is considered to be an orphan receptor as it has no known Ligand biochemistry ligand ... or heterodimers upon ligand binding. HER2 can heterodimerise with any of the other three receptors ... a variety of signaling pathways. Signal transduction Signaling pathways activated by HER2 ... must be tightly regulated to prevent uncontrolled cell growth from occurring. HER2 and cancer Amplification ... carcinoma overexpressing HER2 neu journal Int J Gynaecol Obstet volume 102 issue 2 pages 128 31 year 2008 pmid 18555254 doi 10.1016 j.ijgo.2008.04.008 ref HER2 is co localized, and, most of the time ... cell, gastric, and esophageal tumours. HER2 proteins have been shown to form clusters in cell membranes ... journal author Kaufmann R, M ller P, Hildenbrand G, Hausmann M, Cremer C title Analysis of Her2 ... 2818.2010.03436.x ref Drugs targeting HER2HER2 is the target of the monoclonal antibodies monoclonal ... HER2 is over expressed. An important downstream effect of trastuzumab binding to HER2 is an increase ..., Franz Pruefer, Robert Bast. title HER2 targeting antibodies modulate the cyclin dependent kinase inhibitor ... dimerization of HER2 and HER3 receptors, is in advanced clinical trials. Additionally, NeuVax ... cancer cells that express HER2. It has entered phase 3 clinical trials. It is revealed that patients with ER Estrogen receptor positive HER2 compared with ER HER2 breast cancers may actually benefit ... 05 100506112557.htm laysource ScienceDaily ref Over expression of HER2 can also be suppressed by the amplification ... more details
File Ectodomain shedding en.svg thumb 400px right Diagram of an ectodomain shedding ADAM metalloprotease. ADAM A Disintegrin And Metalloproteinase ref name pmid18762209 cite journal author Edwards DR, Handsley MM, Pennington CJ title The ADAM metalloproteinases journal Mol. Aspects Med. volume 29 issue 5 pages 258 89 year 2008 month October pmid 18762209 doi 10.1016 j.mam.2008.08.001 url http linkinghub.elsevier.com retrieve pii S0098 2997 08 00055 1 ref is a family of peptidase proteins. ref cite journal author Wolfsberg TG, Straight PD, Gerena RL, et al. title ADAM, a widely distributed and developmentally regulated gene family encoding membrane proteins with a disintegrin and metalloprotease domain journal Dev. Biol. volume 169 issue 1 pages 378 383 year 1995 pmid 7750654 doi 10.1006 dbio.1995.1152 ref It is also known as the adamalysin family or MDC family metalloproteinase like, Disintegrin like, cysteine rich . ADAMs are classified as sheddase s because they cut off or shed extracellular portions of transmembrane proteins . For example, ADAM10 can cut off part of the HER2 receptor, activating it. ref cite journal last Liu first P.C. coauthors et al. title Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. journal Cancer Biology and Therapy volume 5 pages 657 664 year 2006 pmid 16627989 issue 6 doi 10.4161 cbt.5.6.2708 ref Therapeutic ADAM inhibitors can potentiate anti cancer therapy. Citation needed date March 2007 It is categorized under EC number 3.4.24.46 . Family members are ADAM2 ADAM7 ADAM8 ADAM9 ADAM10 ADAM11 ADAM12 ADAM15 ADAM17 ADAM18 ADAM27 ADAM19 ADAM20 ADAM21 ADAM31 ADAM22 ADAM23 ADAM28 ADAM29 ADAM30 ADAM33 See also ADAMTS A Disintegrin And Metalloproteinase with Thrombospondin Motifs family Ectodomain shedding References reflist External links MeshName ADAM Proteins http www.healthvalue.net sheddase.html Metalloproteinases Glycoproteins DEFAULTSORT A Disintegrin And Metallop ... more details
data type mab mab type mab source zu o target HER2 neu Clinical data tradename Herceptin Drugs.com ... is a monoclonal antibody that interferes with the HER2 neu Receptor biochemistry receptor . Its ... cancers, HER2 is over expressed, and causes breast cells to reproduce uncontrollably. ref name ... is an antibody that binds selectively to the HER2 protein. When it binds to defective HER2 proteins, the HER2 protein no longer causes cells in the breast to reproduce uncontrollably. This increases ... with uterine papillary serous carcinoma s that overexpress HER2 neu. ref cite journal author Santin ... or recurrent endometrial carcinoma overexpressing HER2 neu journal Int J Gynaecol Obstet volume ... The HER2 gene also known as HER2 neu and ErbB2 gene is amplified in 20 30 of early stage breast ..., HER2 may send signals without mitogens arriving and binding to any receptor, making it overactive. The HER2 ... Cancer Institute accessdate 19 April 2011 ref The EGF pathway includes the receptors HER1 EGFR , HER2, HER3, and HER4 ligand binding and homo heterodimerization is required to initiate the pathway. HER2 ... and cell proliferation signals. In cancer cells the HER2 protein can be expressed up to 100 times ... HER2 Disease in the Metastatic and Adjuvant Settings url http www.medscape.org viewarticle 557474 ... proliferative signaling and hence tumor formation. Overexpression of HER2 also causes deactivation of checkpoints, allowing for even greater increases in proliferation. HER2 extends through the cell ... of the HER family of receptors. Those bound receptors then link protein dimer dimerize with HER2, activating it. HER2 then sends a signal to the inside of the cell. The signal passes through different ... E title Biologic and therapeutic role of HER2 in cancer journal Oncogene year 2003 volume 22 pages ... the cytoplasm to the nucleus, to keep the cycle under control. When HER2 always sends signals, p27Kip1 ... segment of the HER2 neu receptor. Cells treated with trastuzumab undergo arrest during the G1 ... more details
of HER2 metastatic breast cancer ref ref http www.ama assn.org resources doc usan trastuzumab ... www.clinicaltrial.gov ct2 results?term T DM1 ref especially of the HER2 positive type. ref cite journal url http www.medwire news.md 46 90740 Oncology Antibody drug conjugate feasible as HER2 positive breast cancer treatment.html title Antibody drug conjugate feasible as HER2 positive breast cancer ... patients with HER2 positive advanced breast cancer were very encouraging. ref name ABC II cite news ... anti E2 80 91her2 therapy in metastatic her2 positive breast cancer title T DM1 Antibody Drug Conjugate Outperforms Standard Anti HER2 Therapy in Metastatic HER2 positive Breast Cancer date 1 Nov 2011 ref It is starting multiple phase III trials for HER2 positive metastatic breast cancer ref name ... more details
File Ectodomain shedding en.svg thumb Diagram of an ectodomain shedding ADAM metalloprotease. Sheddases are membrane bound enzyme s that cleave extracellular portions of transmembrane protein s, releasing the soluble ectodomain s from the cell surface. Many sheddases are members of the ADAM protein ADAM or aspartic protease BACE protein families. ref cite web author R&D Systems title Need help at the cell surface? Ask your local sheddase. url http www.rndsystems.com cb detail objectname wi06 sheddase.aspx work Cytokine Bulletin date Winter 2006 ref They can activate a transmembrane protein if it is a receptor e.g., HER2 , or cut off the part of the transmembrane protein which has already bound an agonist e.g., in the case of epidermal growth factor receptor EGFR , allowing this agonist to go and stimulate a receptor on another cell. Hence sheddases demultiply the yield of agonists. Sheddase inhibitors active on ADAM10 and ADAM17 can potentiate anti cancer therapy. ref http www.healthvalue.net sheddase.html Healthvalue Sheddases and ADAMs ref References reflist See also Ectodomain shedding Category EC 3.4 Category Membrane proteins hydrolase stub membrane protein stub de Sheddase ru ... more details
line treatment of HER2 positive metastatic breast cancer. Drugs 2012 Feb 12 72 3 353 60 . http ... in the first line treatment of HER2 positive metastatic breast cancer. Drugs 2012 Feb 12 72 ... with placebo plus trastuzumab plus docetaxel, when used as first line treatment for HER2 positive ... cancer , TRYPHAENA HER2 positive stage II III breats cancer and APHINITY HER2 positive nonmetastatic breast cancer . ref name test Keating GM. Pertuzumab in the first line treatment of HER2 positive ... more details
Orphan date May 2011 refimprove date April 2011 A predictive marker is a particular protein or gene that indicates sensitivity or resistance to a specific therapy . The use of predictive markers is becoming increasingly relevant in cancer therapy as it allows for better identification of patients who will respond positively to the therapy. In the clinical setting, predictive markers are limited to use in breast cancer . ref cite journal last Duffy first Michael title Predictive Markers in Breast and Other Cancers A Review journal Clinical Chemistry year 2005 volume 51 pages 494 503 url http www.clinchem.org cgi content full 51 3 494 accessdate 2011 04 04 issue 3 pmid 15637130 month March ref Expression of estrogen and progesterone receptor s can determine the benefits of hormone therapy , whilst the benefit of treating breast cancer patients with Trastuzumab herceptin Trastuzumab is determined by the expression of HER2. There are many advantages to utilizing a predictive marker in cancer therapy including better patient management minimizing unnecessary suffering from side effects with ultimately the wrong treatment choice, reducing loss of precious time whilst determining whether a therapy will provide any benefit, and a reduction in cost to both the patient and the wider health community. References reflist Category Cancer treatments ... more details
Symphony is a suite of assay s that analyze hundreds of genes in an individual breast cancer . The test is marketed by Agendia . The results aid physicians in deciding appropriate treatment for each patient. There are four breast cancer tests within the Symphony suite MammaPrint , which assists physicians and patients in complex chemotherapy decisions by giving a clear and unambiguous high or low result of the risk of metastasis during the period when chemotherapy is effective the first five years after diagnosis TargetPrint, which identifies the presence of certain receptors and helps identify patient candidates for hormonal treatment and targeted therapies ref Roepman P, Horlings HM, 2009 Microarray Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer Clin Cancer Res. 15 22 7003 11 ref BluePrint, which identifies three different biological subgroups that react differently to specific therapies ref http www.agendia.com pages blueprint 324.php Introducing BluePrint A Molecular Subtyping Profile for Breast Cancer ref TheraPrint, which indicates potential treatment options for non responsive metastatic breast cancer patients. References Reflist External links Agendia http www.agendia.com Categories Category Articles created via the Article Wizard Category Breast cancer ... more details
Deleted image removed File AU565 synonomous with SkBr3 Cells 20x Magnification.jpg thumb right AU565 Cells 20x Magnification Synonymous with SkBr3 Cells SkBr3 is a cell line isolated by the Memorial Sloan Kettering Cancer Center in 1970. It was derived from a pleural effusion due to an adenocarcinoma originating in the breast of a 43 year old, caucasian female. The cell line over expresses the HER2 gene product. ref name cite1 cite web title AATC Product Description url http www.lgcstandards atcc.org LGCAdvancedCatalogueSearch ProductDescription tabid 1068 Default.aspx?ATCCNum HTB 30&Template cellBiology accessdate 26 February 2012 ref The SkBr3 line is synonymous derived from the same patient with the AU565 cell line. ref cite web title LBL Breast Cancer Cell Collection Cell Line AU565 url http cancer.lbl.gov breastcancer viewline.php?id 4 accessdate 26 February 2012 ref The SkBr3 cell line has been used in studies seeking to overcome Herceptin resistance to HER2 overexpressing breast cancer. ref cite web title Overcoming Trastuzumab Resistance in HER2 Overexpressing Breast Cancer Cells by Using a Novel Celecoxib Derived Phosphoinositide Dependent Kinase 1 Inhibitor url http molpharm.aspetjournals.org content 70 5 1534.full accessdate 26 February 2012 ref The cells are considered biosafety level 1. ref name cite1 References Reflist Category Cell lines ... more details
Expressing HER2 Full Text View ClinicalTrials.gov cite web url http clinicaltrials.gov ct2 ... Expressing HER2 Full Text View ClinicalTrials.gov format work accessdate ref Synthesis Image ... more details
kinase inhibitor TKI that irreversibly inhibits human epidermal growth factor receptor 2 Her2 and epidermal ... to these standard therapies. Because of its additional activity against Her2, it is investigated for breast cancer as well as other EGFR and Her2 driven cancers. ref name Minkovsky References reflist ... more details
The Association of Consulting Engineers New Zealand ACENZ is New Zealand s main business association representing engineer s providing consultancy services in a wide range of disciplines. It was founded in 1959 as the consulting division of IPENZ , though it has been a separate entity since 1970. ref name ABOUT About ACENZ Innovate NZ , Brochure of the 2007 ACENZ Awards of Excellence , Page 2 ref It has 176 corporate members with a total of around 8,500 staff 2007 data , ref name ABOUT , up from about 5,800 in 2001. ref name HER1 http www.nzherald.co.nz section 3 story.cfm?c id 3&objectid 333478 Engineers forge ahead with 100m exports New Zealand Herald , Tuesday 18 December 2001 ref Apart from its functions as a representative of the interests of its member companies, it annually judges engineering awards for the most innovative and exceptional engineering projects of New Zealand. ref name AWARDS Innovate NZ 2007 Awards of Excellence Innovate NZ , Brochure of the 2007 ACENZ Awards of Excellence , Page 4 ref ref name HER2 http www.nzherald.co.nz section 3 story.cfm?c id 3&objectid 2350070 Beca Carter wins two Innovate NZ awards New Zealand Herald , Monday 19 August 2002 ref References references External links http www.acenz.org.nz ACENZ Online official association website Category Consulting Category Engineering societies Category Organisations based in New Zealand Since it is generally known as ACENZ, not by the long form, it should be under A Category 1959 establishments Category Learned societies of New Zealand ... more details
also be added to the regimen depending on the tumor characteristics i.e. HER2 neu status and risk of relapse ... to test for the HER2 gene to see whether the women might benefit from the drug Herceptin. Prof Bartlett said that assessment for CEP17 could be easily carried out in the same FISH analysis as for HER2 ... more details
of early and late stage HER2 positive breast cancer. ref cite news url http www.genengnews.com ... 2 Her2 and epidermal growth factor receptor EGFR kinases. ref name pmid17311002 cite journal author ... more details
of the ERBB kinases, including EGFR, ERBB2 HER2 and ERBB4 HER4 . The protein chains are colored ... to Trastuzumab. It is revealed that patients with ER HER2 compared with ER HER2 breast cancers ... Status of HER2 Breast Cancer Correlates With Response to Anti HER Therapies. ScienceDaily May ... more details
Small molecule 2001 CML Lapatinib Erb1 Erb2 GlaxoSmithKline GSK Small molecule 2007 HER2 Breast Lenvatinib ... Monoclonal antibody 1998 HER2 breast cancer Vandetanib RET proto oncogene RET VEGFR Epidermal growth ... more details
hypothermia . ref name HER2 cite web url http www.nzherald.co.nz section 1 story.cfm?c id 1&objectid ... outside the cave mouth, as well as alleged fatigue of the skipper. ref name HER2 Excitor II Around ... more details
the HER2 growth receptor pathway. ref name futuredrugs It is used in combination therapy for HER2 ... breast cancer whose tumors overexpress HER2 ErbB2 . ref name FDA cite web url http www.ncbi.nlm.nih.gov ... women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor ... oncogene s, Epidermal growth factor receptor EGFR epidermal growth factor receptor and HER2 neu ... expression of HER2 neu can be responsible for certain types of high risk breast cancers in women. ref ... processes by binding to the ATP binding pocket of the EGFR HER2 protein kinase protein domain domain ... in treatment naive, ER EGFR HER2 breast cancer patients now often called triple positive and in patients who have HER2 positive advanced breast cancer that has progressed after previous treatment with other ... capecitabine for HER2 positive advanced breast cancer journal N. Engl. J. Med. volume 355 issue 26 pages ... for lapatinib use only in combination therapy combination with capecitabine for HER2 positive breast ... more details
In combination with low doses of herceptin , selective ADAM10 inhibitors decrease proliferation in HER2 neu HER2 over expressing cell lines while inhibitors, that do not inhibit ADAM10, have no impact. These results are consistent with ADAM10 being a major determinant of HER2 shedding, the inhibition ... cancers with active HER2 signaling. ref name pmid16627989 cite journal author Liu PC, Liu X, Li Y, et al title Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 ... more details
is a mechanism of Trastuzumab resistance in HER2 breast cancer patients. Thus, co treatment ..., et al. Cyclin E amplification overexpression is a mechanism of trastuzumab resistance in HER2 breast ... more details
, and was temporary home of 559 officers and 3,269 ratings. ref name HER2 cite web url http www.nzherald.co.nz .... ref name HER2 Canterbury was deployed to East Timor as part of the Australian led INTERFET peacekeeping ... vessels . ref name HER2 Decommissioning and fate After being decommissioned in 2005, there was talk ... could be in the millions. ref name HER2 The ship itself had been sold to the trust for a symbolic ... more details
Kasian Franks is the founder, Chief executive officer CEO , and CVO Disambiguation needed date June 2011 of Mimvi . Career Franks was born and raised in Berkeley California . At UC Berkeley , he studied Computer Science and Software Engineering . While at UC Berkeley, Franks consulted for Genentech and eventually started his own company in 1993, The Berkeley Integration Group , which later landed Genentech as its first client. While working with Genentech, Franks helped develop and manage the Pharmaceutical Recipe Builder PRB , a toolset for construction and revision control of genetic recipes used to design breast cancer, asthma and blood clotting drugs HER2, DNASE and Protein A . ref http lmi.seeqpod.com kasian franks CV KF.html ref Franks worked as software engineer and product developer specializing in pattern matching algorithms and tools for companies and organizations such as Sun Microsystems , Oracle Corporation Oracle , Motorola , Tivo , mPower , and X Mine . Franks worked at the U.S. Department of Energy s Lawrence Berkeley National Laboratory LBNL , Life Sciences Division, as a Genomic Research Scientist from 2002 2005, where, along with Raf Podowski, and Connie Myers, he developed the technology behind SeeqPod . Franks began to study biomimetics along with pattern matching in data and nature. This led to 5 patents in the area of search and discovery. Later he went on to start SeeqPod Inc. a music search, discovery and pattern matching company in which the U.S. Department of Energy , along with Lawrence Berkeley National Laboratory , holds a 5 stake. Under Steven Chu and Lawrence Berkeley National Lab , Franks and SeeqPod won a 2008 R&D 100 Award for biomimetic search engines . A number of record companies have attempted to sue SeeqPod, including Warner Music Group , Elektra Records , Rhino Records , and most recently EMI and Capitol Records . ref http www.eff.org deeplinks 2008 01 latest test dmca safe harbors warner sues seeqpod ref Franks formerly held ... more details
Encyclopedia
top
